Christian Zwingelstein


Christian has over 25 years’ experience in clinical development, both in mid size as well as large pharmaceutical companies. As a clinical scientist, he participated in Phase 1 to Phase 3 trials. He was involved in the development of systemic anti infectives, including a pathogen specific anti Pseudomonas antibiotic, and two projects evaluated in the treatment of subjects with severe sepsis / septic shock. He gained experience in the development of inhaled antibiotics. Lately he gained experienced in early-stage development. At ANTABIO, Christian is in charge of the implementation of the Phase 1 clinical program, in particular the design and management of the ANT3310 First in Human study.